PMC9744936_01
Effect of various treatments on the hemoglobin and reticulocyte count for patient 1.
fimmu-13-1055473-g001.jpg
PMC9744936_01_fimmu-13-1055473-g001.jpg
f1
Her hemoglobin remains stable (7.2 - 9.5g/dL) since ( Figure 1 ).
PMC9744936_02
PMC9744936_03
Donor specific antibody response to daratumumab.
fimmu-13-1055473-g002.jpg
PMC9744936_03_fimmu-13-1055473-g002.jpg
f2
Due to failure of IST, work up for haploidentical HSCT was done which showed presence of donor specific antibodies (DSA), for which she received weekly daratumumab infusions (16 mg/kg/dose) for 5 weeks with a significant reduction in DSA and was able to receive a HSCT from a previously unsuitable haplo-identical donor ( Figure 2 ).